FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
k

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Osborne Matthew Scott					2. Issuer Name and Ticker or Trading Symbol Unum Therapeutics Inc. [UMRX]						(Che	5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Own				ner
(Last) (First) (Middle) C/O UNUM THERAPEUTICS INC. 200 CAMBRIDGE PARK DRIVE, SUITE 3100					3. Date of Earliest Transaction (Month/Day/Year) 02/11/2020						,	X Officer (give title below) Other (specify below) Chief Financial Officer				
(Street) CAMBRIDGE MA 02140 (City) (State) (Zip)				4.	. If Ame	endment, [Oate o	of Original Fil	ed (Month/Da	ay/Year)	Line	Form fi	led by One led by More	Repo	(Check App rting Person One Report	
		Ta	ble I - Non-De	erivati	ve Se	ecurities	s Ac	quired, D	isposed o	of, or Be	neficially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				е	Execution Date		Date	Code (Instr.			ed (A) or etr. 3, 4 and 5	Beneficia Owned F	s Formally (D) (in the collowing (in the collowi		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership
								Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)			Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	лі(э)		
Stock Option	\$0.8	02/11/2020		A		160,400		(1)	02/11/2030	Common Stock	160,400	\$0.00	160,40	0	D	

Explanation of Responses:

1. 25% of the shares vests on February 11, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.

Remarks:

/s/ Amoli Pandya, Attorney-in-02/13/2020 Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.